Novavax, Inc. (NVAX)
After hours:
| Previous close | 16.83 |
| Open | 16.88 |
| Bid | 16.48 x 1000 |
| Ask | 16.66 x 800 |
| Day's range | 15.56 - 17.21 |
| 52-week range | 15.56 - 236.50 |
| Volume | |
| Avg. volume | 4,986,677 |
| Market cap | 1.295B |
| Beta (5Y monthly) | 1.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -17.51 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 78.17 |
- Zacks
Novavax (NVAX) COVID Jab Gets Expanded Label in WHO's EUL
The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.
- Zacks
Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
- PR Newswire
World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an updated Emergency Use Listing (EUL) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series of two doses in adolescen
